Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2005

Open Access 01-12-2005 | Research article

Correlation between human papillomavirus infection and bladder transitional cell carcinoma

Authors: MR Barghi, A Hajimohammadmehdiarbab, SMM Hosseini Moghaddam, B Kazemi

Published in: BMC Infectious Diseases | Issue 1/2005

Login to get access

Abstract

Background

To determine the association of human papillomavirus infection (HPV) and transitional cell carcinoma (TCC).

Methods

Using polymerase chain reaction, fifty-nine bladder tissue specimens of patients with transitional cell carcinoma of bladder compared with 20 bladder samples of cases with non-neoplastic disorders.

Results

Male to female ratio was similar in the two groups (50/9 vs. 16/4, P = 0.62). Mean age was 67 ± 10.8 years and 52 ± 20.3 years in the case and control groups, respectively (P = 0.6). Of the 59 tissue specimens with diagnosis of transitional cell carcinoma, HPV DNA was detected in 21 (35.6%) samples, while it was present in only one sample (5%) in the control group (P = 0.008). HPV18 was the most common type of virus with the incidence rate of 17/21(81%).

Conclusion

HPV might play a causative role in transitional cell carcinoma of bladder in our geographic area.
Literature
1.
Kamel D, Paakko P, Pollanen R, Vahakangas K, Lehto VP, Soini Y: Human papillomavirus DNA and abnormal p53 expression in carcinoma of the urinary bladder. APMIS. 1995, 103: 331-338.CrossRefPubMed
2.
Sano T, Sakurai S, Fukuda T, Nakajima T: Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Pathol Int. 1995, 45: 506-512.CrossRefPubMed
3.
Aynaud O, Tranbaloc P, Orth G: Lack of evidence for a role of human papillomaviruses in transitional cell carcinoma of the bladder. J Urol. 1998, 159: 86-89.CrossRefPubMed
4.
Chang F, Lipponen P, Tervahauta A, Syrjanen S, Syrjanen K: Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction. J Urol. 1994, 152: 1429-1433.PubMed
5.
Sinclair AL, Nouri AM, Oliver RT, Sexton C, Dalgleish AG: Bladder and prostate cancer screening for human papillomavirus by polymerase chain reaction: conflicting results using different annealing temperatures. Br J Biomed Sci. 1993, 50: 350-354.PubMed
6.
Gross G, Pfister H: Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl). 2003, 193: 35-44. 10.1007/s00430-003-0181-2.CrossRef
7.
Castellsague X, Bosch FX, Munoz N: The male role in cervical cancer. Salud Publica Mex. 2003, 45 (Suppl 3): S345-53.CrossRefPubMed
8.
Park TC, Kim CJ, Koh YM, Lee KH, Yoon JH, Kim JH, etal: Human papillomavirus genotyping by the DNA chip in the cervical neoplasia. DNA Cell Biol. 2004, 23: 119-125. 10.1089/104454904322759939.CrossRefPubMed
9.
Tekin MI, Tuncer S, Aki FT, Bilen CY, Aygun C, Ozen H: Human papillomavirus associated with bladder carcinoma? Analysis by polymerase chain reaction. Int J Urol. 1999, 6: 184-186. 10.1046/j.1442-2042.1999.06435.x.CrossRefPubMed
10.
Mvula M, Iwasaka T, Iguchi A, Nakamura S, Masaki Z, Sugimori H: Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma?. J Urol. 1996, 155: 471-474. 10.1097/00005392-199602000-00013.CrossRefPubMed
11.
Kitamura T, Yogo Y, Ueki T, Murakami S, Aso Y: Presence of human papillomavirus type 16 genome in bladder carcinoma in situ of a patient with mild immunodeficiency. Cancer Res. 1988, 48 (24 Pt 1): 7207-PubMed
12.
Querci della Rovere G, Oliver RT, McCance DJ, Castro JE: Development of bladder tumour containing HPV type 11 DNA after renal transplantation. Br J Urol. 1988, 62: 36-38.CrossRefPubMed
13.
Agliano AM, Gradilone A, Gazzaniga P, Napolitano M, Vercillo R, Albonici L, etal: High frequency of human papillomavirus detection in urinary bladder cancer. Urol Int. 1994, 53: 125-129.CrossRefPubMed
14.
Fan X, Liu Y, Chen JJ: Activation of c-Myc contributes to bovine papillomavirus type 1 E7-induced cell proliferation. J Biol Chem. 2003, 278: 43163-65. 10.1074/jbc.M306008200.CrossRefPubMed
15.
Patel D, Incassati A, Wang N, McCance DJ: Human papillomavirus type 16 e6 and e7 cause polyploidy in human keratinocytes and up-regulation of g(2)-m-phase proteins. Cancer Res. 2004, 64: 1299-306. 10.1158/0008-5472.CAN-03-2917.CrossRefPubMed
16.
LaRue H, Simoneau M, Fradet Y: Human papillomavirus in transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 1995, 1: 435-40.PubMed
17.
Gazzaniga P, Vercillo R, Gradilone A, Silvestri I, Gandini O, Napolitano M: Prevalence of papillomavirus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer. J Med Virol. 1998, 55: 262-7. 10.1002/(SICI)1096-9071(199808)55:4<262::AID-JMV2>3.0.CO;2-Z.CrossRefPubMed
Metadata
Title
Correlation between human papillomavirus infection and bladder transitional cell carcinoma
Authors
MR Barghi
A Hajimohammadmehdiarbab
SMM Hosseini Moghaddam
B Kazemi
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2005
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-5-102

Other articles of this Issue 1/2005

BMC Infectious Diseases 1/2005 Go to the issue

Research article

Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Research article

Dog filariosis in the Lazio region (Central Italy): first report on the presence of Dirofilaria repens

Research article

Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach

Research article

Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study

Research article

A nested-PCR with an Internal Amplification Control for the detection and differentiation of Bartonella henselae and B. clarridgeiae: An examination of cats in Trinidad

Research article

Hepatitis E virus infection in hemodialysis patients: A seroepidemiological survey in Iran
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits